Please use this identifier to cite or link to this item: doi:10.22028/D291-35478
Title: COVID-19 and Intracranial Hemorrhage: A Multicenter Case Series, Systematic Review and Pooled Analysis
Author(s): Schmidbauer, Moritz L.
Ferse, Caroline
Salih, Farid
Klingner, Carsten
Musleh, Rita
Kunst, Stefan
Wittstock, Matthias
Neumann, Bernhard
Schebesch, Karl-Michael
Bösel, Julian
Godau, Jana
Lochner, Piergiorgio
Adam, Elisabeth H.
Jahnke, Kolja
Knier, Benjamin
Schirotzek, Ingo
Müllges, Wolfgang
Notz, Quirin
Dengl, Markus
Güldner, Andreas
Onur, Oezguer A.
Garcia Borrega, Jorge
Dimitriadis, Konstantinos
Günther, Albrecht
on behalf of the IGNITE Study Group
Language: English
Title: Journal of Clinical Medicine
Volume: 11
Issue: 3
Publisher/Platform: MDPI
Year of Publication: 2022
Free key words: COVID-19
intracranial hemorrhage
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) profoundly impacts hemostasis and microvasculature. In the light of the dilemma between thromboembolic and hemorrhagic complications, in the present paper, we systematically investigate the prevalence, mortality, radiological subtypes, and clinical characteristics of intracranial hemorrhage (ICH) in coronavirus disease (COVID-19) patients. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a systematic review of the literature by screening the PubMed database and included patients diagnosed with COVID-19 and concomitant ICH. We performed a pooled analysis, including a prospectively collected cohort of critically ill COVID-19 patients with ICH, as part of the PANDEMIC registry (Pooled Analysis of Neurologic Disorders Manifesting in Intensive Care of COVID-19). Results: Our literature review revealed a total of 217 citations. After the selection process, 79 studies and a total of 477 patients were included. The median age was 58.8 years. A total of 23.3% of patients experienced the critical stage of COVID-19, 62.7% of patients were on anticoagulation and 27.5% of the patients received ECMO. The prevalence of ICH was at 0.85% and the mortality at 52.18%, respectively. Conclusion: ICH in COVID-19 patients is rare, but it has a very poor prognosis. Different subtypes of ICH seen in COVID-19, support the assumption of heterogeneous and multifaceted pathomechanisms contributing to ICH in COVID-19. Further clinical and pathophysiological investigations are warranted to resolve the conflict between thromboembolic and hemorrhagic complications in the future.
DOI of the first publication: 10.3390/jcm11030605
Link to this record: urn:nbn:de:bsz:291--ds-354786
ISSN: 2077-0383
Advisor: Attribution 4.0 International (CC BY 4.0)
Date of registration: 18-Feb-2022
Description of the related object: Supplementary Materials
Related object:
Faculty: M - Medizinische Fakultät
Department: M - Neurologie und Psychiatrie
Professorship: M - Keiner Professur zugeordnet
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
jcm-11-00605.pdf3,01 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons